Latest Articles
Background Superior efficacy of subcutaneous infliximab (CT-P13 SC) over placebo for maintenance therapy in patients with Crohn’s disease (CD) and ulcerative colitis (UC) was demonstrated in the ...
This report presents a novel case of a 40-year-old male with metastatic Crohn’s disease resembling hidradenitis suppurativa, highlighting the complexity of diagnosis and treatment with upadacitinib ...
Background The fecal microbiome of patients with inflammatory bowel diseases (IBD) is characterized by longitudinal variability. It remains unknown if this is caused by decreased resilience of the ...
Background Inflammatory bowel diseases (IBDs) are increasingly recognized as products of the brain–gut axis associated with dysfunctions of the chronic stress response systems. The objectives of this ...
Background Statins reduce the risk of inflammatory bowel disease (IBD), however their effect on IBD disease progression is largely unknown. Methods We linked Swedish healthcare registers and ...
Editor's Choice Articles
Background Although most inflammatory bowel disease (IBD) medications are considered safe during pregnancy, their impact on microRNAs (miRNAs) in breast milk is largely unknown. MiRNAs in milk, ...
Background Down-Regulated in Adenoma (DRA) plays a critical role in intestinal chloride absorption and a decrease in its expression is a key event in diarrheal disorders. Recently, DRA has emerged as ...
Background Perianal fistulizing Crohn’s disease (pfCD) poses significant healing challenges, closely associated with neutrophil extracellular traps (NETs). This study aimed to investigate the ...
Background Given the paucity of long-term longitudinal data for inflammatory bowel disease type unclassified (IBDU), we aimed to clarify IBDU disease course and reclassification rate by presenting ...
Background Intestinal fibrosis, a complex complication of colitis, is characterized by excessive extracellular matrix (ECM) deposition. Estrogen receptor (ER) β may play a role in regulating this ...
Background Inflammatory bowel diseases are chronic disabling conditions with a complex and multifactorial etiology, still incompletely understood. OCTN1, an organic cation transporter, could have a ...
Introduction Carriage of the HLA-DQA1*05 allele is associated with development of antidrug antibodies (ADAs) to antitumor necrosis factor (anti-TNF) therapy in patients with Crohn’s disease. However, ...
Background Inflammatory bowel diseases (IBDs) pose a significant challenge due to their diverse, often debilitating, and unpredictable clinical manifestations. The absence of prognostic tools to ...
Journal Information
Impact Factor
4.5
Editor-in-Chief
Sonia Friedman, M.D.
Deputy Editor
Subra Kugathasan, M.D.
Editorial board
Publish with IBD
Inflammatory Bowel Diseases publishes original basic science, translational, and clinical research regarding pathogenesis, epidemiology, evaluation, and treatment of IBD that will lead to advancements in overall clinical care. Submit your article to contribute to this leading body of research.
Learn more about publishing with the journal
Featured Videos
Video abstract
Thiopurine treatment in ulcerative colitis: a critical review of the evidence for current clinical practice
Video abstract
A survey study of gastroenterologists' attitudes and barriers towards therapeutic drug monitoring of anti-TNF therapy in inflammatory bowel disease
Video abstract
Indeterminate QuantiFERON-TB gold increases likelihood of inflammatory bowel disease treatment delay and hospitalization
Video abstract
Factors associated with length of stay in veterans with inflammatory bowel disease hospitalized for an acute flare
Email alerts
Register to receive table of contents email alerts as soon as new issues of Inflammatory Bowel Diseases are published online.
Sign up
Read and Publish deals
Authors interested in publishing in Crohn's & Colitis 360 may be able to publish their paper Open Access using funds available through their institution’s agreement with OUP.
Find out if your institution is participating
Want access to IBD?
Fill out our simple online form to recommend IBD to your library. Your institution could also be eligible for free or deeply discounted access via our developing countries initiatives.
Recent Supplements
Abstracts from the 2023 Crohn’s & Colitis Congress®
About the Foundation
Professional Education Opportunities
The Foundation is here to support healthcare providers in their efforts to care for patients with IBD through our professional education and training programs. Learn more about our many resources for professionals as well as educational activities.
Learn more
Connect with the Foundation
Stay up to date with the latest news and content from the Foundation:
Become a Foundation Member
By becoming a Professional Member of the Crohn's & Colitis Foundation, you will establish yourself as a leader and specialist in Crohn's disease and ulcerative colitis. In addition, you will gain the support and resources that can help you equip your patients with everything they need to take charge of their digestive diseases.
Learn moreResources to Share
As the nation’s leading source for educational information for Crohn’s disease and ulcerative colitis patients and professionals, the Crohn’s & Colitis Foundation maintains an extensive collection of resources for people diagnosed with these diseases, and other information on IBD.
Learn more
